EGFR mutated non-squamous NSCLC MedDRA version: 20.0 Level: HLGT Classification code 10038666 Term: Respiratory and mediastinal neoplasms malignant and unspecified System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conditions
Interventions
Trade Name: Giotrif
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Afatinib
CAS Number: 850140-73-7
Other descriptive name: AFATINIB DIMALEATE
Concentration unit: mg milligram(s)
Concent
Sponsors
Universitätsmedizin Mainz, Interdisziplinäres Zentrum klinische Studien
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed non-squamous NSCLC harboring EGFR mutation positive but T790M mutation negative by local testing 2. Unresectable stage UICC = IIIb or metastatic stage UICC IV disease 3. TKI naïve for metastatic NSCLC, neoadjuvant or adjuvant chemotherapy allowed 4. At least one evaluable lesion according to RECIST v1.1 5. Age = 18 years 6. ECOG performance status 0 - 2 7. Adequate organ function, defined as all of the following: a. Absolute neutrophil count (ANC) = 1500/mm3. (ANC > 1000/mm3 may be considered in special circumstances such as benign cyclical neutropenia as judged by the investigator and in discussion with the coordinating investigator) b. Platelet count = 75,000/mm3 c. Estimated glomerular filtration rate (eGFR) > 45 ml/min/1.73 m2 according to the Cockcroft-Gault formula (Refer to Appendix 1) d. If history of cardiac comorbidity: Left ventricular function with resting ejection fraction = 50% or above the institutional lower limit of normal (LLN) e. Total Bilirubin = 1.5 times upper limit of normal (ULN), (if related to liver metastases = 3 times ULN). (Patients with Gilbert’s syndrome total bilirubin must be = 4 times institutional upper limit of normal) f. Aspartate amino transferase (AST) or alanine amino transferase (ALT) = 3 times the upper limit of normal (ULN) (if related to liver metastases = 5 times ULN) 8. Recovered from any previous therapy related toxicity to = Grade 1 at before randomization (except for stable sensory neuropathy = Grade 2 and Alopecia) 9. Written informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 76
Exclusion criteria
Exclusion criteria: 1. Any investigational drug within 30 days or hormonal anticancer treatment within 2 weeks prior to randomization (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted) 2. T790M mutation positive tumors (by local testing) 3. Radiotherapy within 2 weeks prior to randomization, except as follows: a. Palliative radiation to target organs other than chest may be allowed up to 1 week prior to randomization b. Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with coordinating investigator prior to enrolling 4. Major surgery within 2 weeks before starting study treatment or scheduled for surgery during the projected course of the study 5. Known hypersensitivity to afatinib or osimertinib or the excipients of any of the trial drugs 6. History or presence of clinically relevant cardiovascular abnormalities such as: a. uncontrolled hypertension b. congestive heart failure NYHA classification of = 3 c. unstable angina or poorly controlled arrhythmia as determined by the investigator d. Myocardial infarction within 6 months prior to randomization e. Clinically important abnormalities in rhythm and conduction as measured by resting electrocardiogram (ECG) (e.g. QTc interval greater than 470 ms) or QTc interval prolongation with signs/symptoms of serious arrhythmia f. Congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or intake of medicinal products that are known to prolong the QTc interval 7. Patients with a past or present medical history of: a. Interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD b. Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient’s ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug c. Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn’s disease, ulcerative colitis, chronic diarrhoea, malabsorption) d. Known active hepatitis B infection (defined as presence of HepB sAg and/or Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier e. Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 5 years and is considered to be cured 8. Pregnancy and contraception: a. Women who are pregnant, nursing, or who plan to become pregnant while in the trial b. Women of child-bearing potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use highly effective methods of birth control that result in a low failure rate of less than 1% per year when used consistently and correctly beginning at informed consent, for the duration of study participation and for at least 2 months for females and 4 months formales after last dose 9. Requiring treatment with any of the prohibited concomitant medications (P-Glycoprotein Inhibitors/Inductors CYP3A4/5 Inhibitors/Inductors) that cannot be stopped for the duration of trial participation or concomitant St. John’s Wort 10. Uncontrolled brain metastases (Patients with brain or subdural metastases are n
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The main objective is to investigate whether the time to EGFR-TKI failure at 24 months is better for the treatment sequence of afatinib followed by osimertinib in the T790M positive group compared to osimertinib.;Secondary Objective: Time to EGFR-TKI failure (afatinib versus osimertinib) Progression-free survival (PFS: afatinib followed by osimertinib or ICT vs osimertinib followed by ICT) Overall Survival (OS) Response Rate (RR) Disease Control Rate (DCR) Safety and Tolerability Symptom control assessed by patient-reported quality of life (QoL);Primary end point(s): Time to EGFR-TKI failure within 24 months for afatinib followed by osimertinib in T790Mpositive group vs osimertinib;Timepoint(s) of evaluation of this end point: at 24 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Time to EGFR-TKI failure (afatinib versus osimertinib) Progression-free survival (PFS: afatinib followed by osimertinib or ICT vs osimertinib followed by ICT) Overall Survival (OS) Response Rate (RR) at 12 months and 24 months Disease Control Rate (DCR) at 12 months and 24 months Safety and Tolerability Symptom control assessed by patient-reported quality of life (QoL) with EQ-5D, EORTC QLQ-C30, EORTC QLQ-LC29;Timepoint(s) of evaluation of this end point: at 24 months | — |
Countries
Germany
Contacts
Public ContactProf. Dr. med. Thomas Wehler
Universitätsklinikum Gießen Marburg
Outcome results
None listed